Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $200000.0.

  • Tarsus Pharmaceuticals' Depreciation & Amortization (CF) changed 0.0% to $200000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $820000.0, marking a year-over-year increase of 1021.51%. This contributed to the annual value of $700000.0 for FY2024, which is 591.4% down from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $200000.0 for Q3 2025, which was down 0.0% from $200000.0 recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $244000.0 in Q4 2023 and a low of $40000.0 during Q4 2021
  • Its 5-year average for Depreciation & Amortization (CF) is $141421.1, with a median of $125000.0 in 2021.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Depreciation & Amortization (CF) surged by 63529.41% in 2021, and later crashed by 4505.49% in 2024.
  • Over the past 5 years, Tarsus Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $40000.0 in 2021, then surged by 145.0% to $98000.0 in 2022, then surged by 148.98% to $244000.0 in 2023, then decreased by 18.03% to $200000.0 in 2024, then changed by 0.0% to $200000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $200000.0 in Q3 2025, compared to $200000.0 in Q2 2025 and $220000.0 in Q1 2025.